Alnylam receives approval for oxlumo™ (lumasiran) in the european union for the treatment of primary hyperoxaluria type 1 in all age groups

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the european commission (ec) has granted marketing authorization for oxlumo™ (lumasiran), an rnai therapeutic, for the treatment of primary hyperoxaluria type 1 (ph1) in all age groups. ph1 is an ultra-rare orphan disease characterized by excessive oxalate production, which can lead to life threatening end-stage renal disease (esrd) and other systemic comp
ALNY Ratings Summary
ALNY Quant Ranking